Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
by from Morbidity and Mortality Weekly Report (MMWR) on (#6QPBF)
This report describes the Advisory Committee on Immunization Practices recommendation for use of the 21-valent pneumococcal conjugate vaccine as an option for some adults.